POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
Advanced Lung Disease and Transplant Clinic, Inova Fairfax Hospital, Falls Church, VA. Electronic address: christopher.king@inova.org.
Christopher S
CS
King
Advanced Lung Disease and Transplant Clinic, Inova Fairfax Hospital, Falls Church, VA.
Steven D
SD
Nathan
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003657:Decision Making; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D007211:Indoles; D011728:Pyridones; D014409:Tumor Necrosis Factor-alpha; C093844:pirfenidone; C530716:nintedanib